



Reference Number *PACRIN-6701#A01PAMDREVW01*

Date: **MAR 22 2012**
NCI Protocol #: *ACRIN-6701*
Local Document Number: *ACRIN-6701*
Local Change #: *PRE ACTIVATION AMENDMENT*
Amendment #: *1*
Version Date: *03/15/2012*
Principal Investigator: *Mark A Rosen, M.D., Ph.D.*

Mitchell D. Schnall, M.D., Ph.D.
American College of Radiology Imaging Network
1818 Market Street 16th Floor
Philadelphia, PA 19103

Dear *Dr. Schnall*:

An amendment to your Protocol, NCI #*ACRIN-6701*, entitled, "*Repeatability Assessment of Quantitative DCE-MRI and DWI: A Multicenter Study of Functional Imaging Standardization in the Prostate*", was received by the Cancer Therapy Evaluation Program of the Division of Cancer Treatment and Diagnosis, National Cancer Institute on *03/19/2012*.


The Amendment has been reviewed with the following status:

- Approved as written.
- Approved with recommendations. See attached review.
- Disapproved. **

****Please note: CTEP amendment approval is all-or-nothing. ALL changes submitted with an amendment that has been disapproved must be resubmitted for approval prior to implementation.**

HIPAA Disclaimer: Decisions about the applicability and implementation of the HIPAA Privacy Rule reside with the researcher and his/her institution. Therefore, the Cancer Therapy Evaluation Program will NOT be reviewing documents for compliance with this regulation. If informed consent forms contain language pertaining to HIPAA authorizations, the informed consent components will be assessed for compliance with the Common Rule and FDA regulations, and the confidentiality section will be reviewed for the listing of collaborators who will have access to the identifiable information.

Sincerely,



Frank I-Kai Lin, M.D.
 Cancer Imaging Program
 Cancer Therapy Evaluation Program
 Division of Cancer Treatment and Diagnosis
 National Cancer Institute